EyePoint’s wet AMD trial continues after safety review By Investing.com

EyePoint’s Phase 3 DURAVYU trials passed a third safety review with no protocol changes, and the company said over 35% of active patients have already received a third dose at Week 56. The stock has been volatile, up 145% over the past year but down 26% year-to-date, while Q1 2026 results missed expectations with EPS of -$0.99 versus -$0.82 consensus and revenue of $0.7 million versus $1.01 million expected. Guggenheim reiterated a Buy rating and a $68 target, with topline LUGANO data expected in mid-2026 and DME data in 2H 2027.

Analysis

EYPT is in the classic pre-data inflection where safety continuity matters almost as much as efficacy. The absence of a protocol change after the last scheduled DSMC review reduces the probability of a late-stage derailment, which is the main reason to own the stock into 1H26; the next repricing event is not the safety update but the topline readout window. That makes the stock more sensitive to enrollment/dosing optics and less to quarterly financial noise, even though the cash burn means equity dilution remains a live overhang if the program slips.

The second-order winner here is the anti-VEGF ecosystem, not just EYPT. If a six-month regimen reads cleanly, the market will immediately re-underwrite treatment-burden reduction across retina care, pressuring incumbent injectables on persistence and scheduler economics rather than pure efficacy. That matters because retina practices are capacity constrained; a successful longer-dosing product changes clinic throughput and could shift formulary share faster than headline vision data alone implies.

The stock likely has asymmetric setup into mid-2026: limited near-term fundamental support, but a large binary payoff if non-inferiority is confirmed and the safety profile remains clean. The contrarian miss is that the current narrative may already be pricing in a “good enough” result, while the real upside requires not just non-inferiority but credible adoption economics versus aflibercept. On the downside, any hint of efficacy slippage, injection burden not translating into real-world use, or a financing event before data would compress the multiple quickly because the market is paying for duration that the balance sheet cannot fully self-fund.

Key Decisions for Investors

• Stay constructive but only as a catalyst trade: initiate/maintain a small long EYPT position into mid-2026 with a hard stop on any clinical delay or financing announcement; target is a binary rerating on topline data, not quarterly operating improvement.
• Buy call spreads on EYPT 3-6 months before topline data rather than stock outright if liquidity allows; the setup favors defined-risk convexity because implied volatility should rise as the readout approaches.
• If already long EYPT, hedge with a partial short in a large-cap retina/ophthalmology proxy or biotech ETF to isolate idiosyncratic trial risk; the trade is about clinical alpha, not market beta.
• Do not add aggressively after this safety update alone; treat it as de-risking, not de-risked. The next meaningful entry point is on a broad biotech pullback or after a financing catalyst if the trial timeline stays intact.
• For event-driven accounts, consider a pair trade: long EYPT vs. short a basket of incumbent anti-VEGF exposure ahead of the 1H26 readout, on the thesis that a positive six-month regimen would pressure share and pricing expectations for older treatment paradigms.